ReviewMetabolic brain disease2007
Tryptophan, adenosine, neurodegeneration and neuroprotection.
Review in Metabolic brain disease, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial.Journal of neuroinflammation · 2021Trial
- The Multifaceted Role of L-Type Amino Acid Transporter 1 at the Blood-Brain Barrier: Structural Implications and Therapeutic Potential.Molecular neurobiology · 2025Review
- Physical activity and glioblastoma: a paradigm shift in neuro-oncology therapy.Frontiers in oncology · 2025Review
- Redefining Roles: A Paradigm Shift in Tryptophan-Kynurenine Metabolism for Innovative Clinical Applications.International journal of molecular sciences · 2024Review
- The possible role of gut microbiota dysbiosis in the pathophysiology of delirium in older persons.Microbiome research reports · 2023Review
- Involvement of kynurenine pathway between inflammation and glutamate in the underlying etiopathology of CUMS-induced depression mouse model.BMC neuroscience · 2022Article
- An integrated cytokine and kynurenine network as the basis of neuroimmune communication.Frontiers in neuroscience · 2022Review
- Pathomechanisms of Non-Traumatic Acute Brain Injury in Critically Ill Patients.Medicina (Kaunas, Lithuania) · 2020Review
- Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NADFrontiers in immunology · 2020Article
- Blood-brain barrier permeability and physical exercise.Journal of neuroinflammation · 2019Review
- Kynurenine is correlated with IL-1β in plasma of schizophrenia patients.Journal of neural transmission (Vienna, Austria : 1996) · 2018Article
- In Vivo Neuroprotective Effect of Histidine-Tryptophan-Ketoglutarate Solution in an Ischemia/Reperfusion Spinal Cord Injury Animal Model.The Korean journal of thoracic and cardiovascular surgery · 2016Article
- Tryptophan Biochemistry: Structural, Nutritional, Metabolic, and Medical Aspects in Humans.Journal of amino acids · 2016Review
- Methionine Exposure Alters Glutamate Uptake and Adenine Nucleotide Hydrolysis in the Zebrafish Brain.Molecular neurobiology · 2016Article
- The guanosine-adenosine interaction exists in vivo.The Journal of pharmacology and experimental therapeutics · 2014Article
- Unexpected effects of peripherally administered kynurenic acid on cortical spreading depression and related blood-brain barrier permeability.Drug design, development and therapy · 2013Article
- Long-term proline exposure alters nucleotide catabolism and ectonucleotidase gene expression in zebrafish brain.Metabolic brain disease · 2012Article
- Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine.Psychopharmacology · 2012Article
- Kynurenine Pathway in Skin Cells: Implications for UV-Induced Skin Damage.International journal of tryptophan research : IJTR · 2012Article
- The tryptophan metabolite 3-hydroxyanthranilic acid plays anti-inflammatory and neuroprotective roles during inflammation: role of hemeoxygenase-1.The American journal of pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review summarises the potential contributions of two groups of compounds to cerebral dysfunction and damage in metabolic disease. The kynurenines are oxidised metabolites of tryptophan, the kynurenine pathway being the major route for tryptophan catabolism in most tissues. The pathway includes quinolinic acid -- an agonist at N-methyl-D-aspartate (NMDA) receptors, kynurenic acid -- an antagonist at glutamate and nicotinic receptors, and other redox active compounds that are able to generate free radicals under many physiological and pathological conditions. The pathway is activated in immune-competent cells, including glia in the central nervous system, and may contribute substantially to delayed neuronal damage following an infarct or metabolic insult. Adenosine is an ubiquitous purine that can protect neurons by suppressing excitatory neurotransmitter release, reducing calcium fluxes and inhibiting NMDA receptors. The extent of brain injury is critically dependent on the balance between the two opposing forces of kynurenines and purines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.